ArticleGastro hep advances2026
Fiber-Dependent Microbiome Glycine Lipids Ameliorate Steatotic Liver Disease in Mice via Mitochondrial Enhancement.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Oral and gut Methods: Microbiome-derived GLs were quantified in murine systemic and portal blood, intestinal lymph, and in mouse and human liver using targeted mass spectrometry. Their biological effects were assessed in mouse and cell culture models of diet-induced liver disease following treatment with L654- and L1256-enriched lipid extracts. Results: L654 and L1256 species were detected in mouse serum, portal plasma, intestinal lymph, and liver, as well as in human liver tissue. A Western-type high-fat diet lowered fecal and hepatic microbiome GLs, whereas fermentable fiber supplementation restored fecal levels (∼7-fold increase), with hepatic GL content showing an inverse association with liver triglycerides. In a 22-week diet-induced MASLD model, administration of L654- or L1256-enriched lipids for 8 weeks significantly reduced hepatic steatosis and histopathological progression. Treatments enhanced mitochondrial DNA content and metabolic function in liver and HepG2 cells. L1256 increased hepatic triggering receptor expressed on myeloid cells 2 expression, associated with lipid sensing and MASLD protection, while L654 modulated splenic cluster of differentiation 4 Conclusion: Microbiome-derived GLs are diet-sensitive molecules that protect against MASLD via mitochondrial enhancement, revealing a novel nutritional-microbial axis for liver disease intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.